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Abstract
Purpose Understanding treatment satisfaction (TS) for
diabetes is increasingly important as treatment options
increase. This study examines treatment satisfaction with
NovoMix
 30 in an observational study in patients with
type 2 diabetes.
Methods The DiabMedSat assesses Overall, Treatment
Burden, Symptom and Efﬁcacy Treatment Satisfaction.
The impact of type of pretreatment variables on TS was
examined by ANOVA at baseline and week 26. Satisfac-
tion at week 26 was examined by t-test and effect size.
Linear regression models examined impact of prior treat-
ment factors (age, gender, duration of diabetes, type of
prior treatment and diabetes-related comorbidities) and
current treatment factors (weight gain, hypoglycemic
events, reaching therapeutic goal) on TS.
Results The data set comprised 17,488 persons. Prior
treatment with insulin had a more positive impact on
baseline satisfaction. At week 26, there were no differences
between type of prior treatment groups in Overall, Symp-
toms and Burden TS. Current treatment with NovoMix 30
signiﬁcantly improved TS. Regression analyses examining
the combined effect of pretreatment factors and current
treatment factors found that all factors except for age-
impacted TS although the domains impacted varied.
Conclusions Patients treated with NovoMix 30 reported
improved treatment satisfaction, and the improvement is
considered clinically meaningful to patients.
Keywords Treatment satisfaction  Observational
study  Diabetes mellitus
Abbreviations
BMI Body mass index
Insulin ? OAD Those taking insulin along with an oral
treatment
PRO Patient-reported outcome
TS Treatment satisfaction
Background
Understanding treatment satisfaction for diabetes is espe-
ciallyimportant giventheeverincreasingrangeoftreatment
options for patients with diabetes. Treatment satisfaction
(TS) is a key patient-reported outcome (PRO) as it has been
found to impact patient compliance [1, 2], cost of care [3, 4]
and self-management behaviors [5], as well as signiﬁcantly
differ between drug treatment options [6, 7]. The treatment
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insulin [8], the most potent drug available to achieve gly-
cemic targets [9]. Unfortunately, insulin use often involves
negative perceptions and may present an emotional and
logistical hurdle leading to patient resistance to treatment
[10–12], and it has been found that, when examining the
willingness of type 2 insulin-naı ¨ve diabetic patients to begin
insulin, negative attitudes toward insulin are common [13].
Persons with diabetes who perceive injecting insulin as
burdensomemayexperiencemorenegativehealthoutcomes
[14],whereaspatientswhoaresatisﬁedwiththeirtreatments
are more likely to maintain positive physical and psycho-
logical health [15].
Unfortunately, patient characteristics such as age and
gender as well as treatment outcomes such as the experi-
ence of side effects, which may differentially inﬂuence
treatment satisfaction depending upon the stage of treat-
ment (treatment initiation vs. during treatment), are not
well understood [16]. Studies have reported that treatment
satisfaction may be positively or negatively associated with
age [17–20]. Duration of diabetes has been shown to pre-
dict poorer quality of life and poorer glycemic control [21,
22]. Several studies have observed an association between
treatment satisfaction and type of treatment (e.g., insulin
vs. oral, type of insulin delivery device) [7, 23–30], and
overall treatment satisfaction has been shown to be sig-
niﬁcantly improved after switching treatment from orals or
orals with insulin to treatment with Biphasic Insulin Aspart
30 [31]. At least three studies reported reduced treatment
satisfaction among women [23, 32, 33]. Diabetes-related
comorbidities such as neuropathy have been found to
predict decreased treatment satisfaction [16, 23, 32, 33].
Previous research has also shown that concerns with
treatment side effects, especially hypoglycemia and weight
gain, can negatively affect patient perceptions of insulin
therapy and lead to diminished treatment efﬁcacy. Fear of
weight gain may increase a patient’s psychological and
treatment burden, diminishing treatment satisfaction [34,
35]. Two studies found that approximately 1/3 of female
subjects with type 1 diabetes omitted insulin in order to
control their weight [36, 37]. Since weight gain is further
associated with insulin resistance, it may also compromise
treatment efﬁcacy [38]. Experiencing hypoglycemic events
has been associated with lower levels of treatment satis-
faction [33, 39], while patients fearful of hypoglycemia
have been reported to limit their blood glucose control
regimen in order to avoid triggering a hypoglycemic event
[34].
Thus, to more accurately characterize the impact of
patient/disease characteristics and treatment outcomes on
treatment satisfaction, a more comprehensive approach
examining potentially relevant pretreatment (e.g., age) and
during treatment (e.g., side effects) variables is necessary
to fully understand factors that exert an inﬂuence on
shaping treatment satisfaction with treatment in diabetes.
The IMPROVE study is a multicenter, 26-week, open-
labeled, non-randomized and non-interventional observa-
tional study of the safety and efﬁcacy of Biphasic Insulin
Aspart 30 (NovoMix 30) for the treatment of diabetes in
routine practice patients with type 2 diabetes [31]. The
DiabMedSat was included in the IMPROVE study as it is
used to examine the impact of treatment on patient-repor-
ted treatment satisfaction, and it is a well validated
disease-speciﬁc PRO measure designed to assess treatment
satisfaction both in persons with type 1 or type 2 diabetes
and across multiple treatment modalities (oral, syringe,
pen) [40, 41]. This study further examines treatment sat-
isfaction in the IMPROVE study by exploring the inﬂuence
of the pretreatment factors (age, gender, duration of dia-
betes, type of prior treatment and diabetes-related comor-
bidities) and the impact of treatment side effects (weight
gain, hypoglycemic events) on both overall treatment sat-
isfaction and on the individual domains of treatment side
effects, burden and efﬁcacy in diabetes.
Methods
Eligible patients for the analyses presented here were any
with type 2 diabetes who needed insulin treatment at the
time of inclusion including newly diagnosed patients.
Analyses were conducted with all patients who had Diab-
MedSat data at both baseline and week 26 (end of study
treatment) and had been on an identiﬁable diabetes treat-
ment prior to entering the IMPROVE study. Patients trea-
ted only with diet/exercise at baseline were dropped from
the analysis and did therefore not complete the question-
naire at baseline.
The 22-item DiabMedSat assesses three treatment sat-
isfaction domains of Efﬁcacy, Treatment Burden and
Symptoms (Side Effects) and Overall treatment satisfaction
and has been translated into multiple languages according
to well-established principles of translation [42]. The
measure has been shown to have acceptable reliability,
validity and responsiveness [41] in patients with diabetes
similar to those enrolled in IMPROVE study [16, 41].
Valid DiabMedSat observations were obtained from seven
countries in the IMPROVE study (Canada, China, India,
Italy, Japan, Poland and Russia) and were part of the same
data set as reported by Valensi et al. [31].
All statistical tests were two-tailed and conducted with
an alpha level of 0.05 as minimal threshold for signiﬁ-
cance. As the DiabMedSat is intended to be used either as a
total score or as independent domains, the testing was
conducted for both the total and domain scores. The scope
of this analysis was aimed at the assessment of treatment
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123satisfaction regardless of cultural differences; hence, the
analyses were conducted on the pooled sample. All anal-
yses conducted were based on an a priori statistical analysis
plan (SAP).
Prior treatment factors
Key patient and diabetes-related factors (age, gender,
duration of diabetes, prior treatment and diabetic-related
comorbidities) that were assessed at baseline and thus
existed before treatment start were classiﬁed as prior
treatment factors. First, the impact of type of pretreatment
(deﬁned as orals only, insulin only and insulin plus orals)
on TS was examined by comparing the means (ANOVA)
of each DiabMedSat domain and overall scores at baseline,
week 26 and the change between baseline and week 26 by
each pretreatment group. The baseline DiabMedSat asses-
sed treatment satisfaction with treatments prior to the
IMPROVE study. Linear regression models, one for each
domain and overall score, were then conducted to examine
the impact that the key prior treatment factors (age, gender,
duration of diabetes, prior treatment, and diabetic-related
comorbidities) had on current satisfaction when examined
together.
An exploratory chi-square was performed to examine,
on an item level, change from baseline to end of study by
pre-study treatment therapy (insulin ? OAD, OAD only).
Current treatment factors
To assess treatment satisfaction with current treatment
(Biphasic Insulin Aspart 30 (NovoMix 30)), change scores
between baseline and week 26 were examined by paired
t-test comparison and by effect size.
Linear regression models were then conducted to
examine the impact of key current treatment factors
(weight gain in kg, hypoglycemic events, achievement of
physician-determined HbA1c goal and study treatment
group) on treatment satisfaction when examined together.
A ﬁnal regression analysis examined the combined
impact of all previously identiﬁed signiﬁcant pretreatment
and current treatment factors on treatment satisfaction
when examined together.
Results
The total IMPROVE data set comprised 19,824 people with
type 2 diabetes: 6 were dropped due to incomplete demo-
graphics (no age or gender); 1,031 were dropped for not
completing the DiabMedSat measure; and 1,299 were
dropped due to lack of information on prior treatment. Thus,
the analytic data set for the analyses reported here was
comprised of 17,488 persons. The average age of the sample
was 57.2 years, with a baseline body mass index (BMI) of
26.2 kg/m
2 and most recent HbA1c of 9.2%. The mean
length of time with diabetes was 6.9 years. Most of the sub-
sample (90.4%) were on oral treatments alone before
starting the study; the rest of the sample were on insulin
with or without oral treatment. The most common reasons
physicians reported for starting patients on treatment were
related to improving treatment efﬁcacy (HbA1c, fasting
glucose, post-prandial blood glucose) or patient treatment
satisfaction. Patients who were dropped were signiﬁcantly
(P\0.001) older (mean age 62.1 vs. 57.2), had a longer
duration of diabetes (mean of 13.9 vs. 6.9 years), a lower
HbA1c (mean 8.8 vs. 9.2) and a higher BMI (mean 31.6 vs.
26.2) than those in the analytic data set (Table 1).
Prior treatment factors
The impact of type of prior treatment showed that at
baseline greater levels of TS (overall and the three
domains) were seen in the cohort using insulin alone.
Baseline satisfaction was slightly lower in those taking
insulin along with an oral treatment (Insulin ? OAD).
At week 26 of the study, patients previously on Insu-
lin ? OAD had a greater satisfaction with treatment efﬁ-
cacy compared to patients on orals alone. There were no
differences between type of prior treatment groups in Di-
abMedSat Overall scores and for the Symptoms and Bur-
den domains.
When examining the change in satisfaction from base-
line to week 26, larger changes were seen in the overall, as
well as in every domain, for patients who were previously
on an oral treatment either alone or in combination with
insulin (Table 2).
Regression analyses examining the combined effect of
pretreatment factors (age, gender, duration of diabetes,
prior treatment and diabetic-related comorbidities) found
that greater age was signiﬁcantly associated with increased
levels of Overall satisfaction and for the Efﬁcacy, and
Burden domains of the DiabMedSat. Those patients having
diabetes for a longer duration were signiﬁcantly associated
with greater levels of satisfaction with the Burden domain.
Subjects on insulin only (pre-study) showed signiﬁcantly
greater levels of satisfaction with the Overall, Efﬁcacy and
Symptoms domains of the DiabMedSat. Having diabetes-
related comorbidities before entering the study were sig-
niﬁcantly associated with greater satisfaction with the
Symptoms domain and lower levels of satisfaction in the
Burden domain (Table 3).
The exploratory chi-square analysis of item level change
from baseline to end of study by pre-study treatment
revealed that the proportion of patients who were ‘‘very or
extremely satisﬁed’’ (highest improvements on scale)
Qual Life Res (2010) 19:1285–1293 1287
123increased signiﬁcantly from baseline to end of study par-
ticularly on questions related to ‘reduce tiredness’, ‘control
blood sugar’ and ‘reduce worries about complications’. For
patients previously on Insulin ± OADs, these questions,
respectively, increased from 12.4, 11.4 and 13.9% at
baseline to 47.6, 49.1 and 39.3% after 26 weeks. For
patients previously on OADs alone, these questions,
respectively, increased from 7.5, 6.9 and 9.3% at baseline
to 50.1, 49.7 and 35% after 26 weeks.
Current treatment factors
Examining the impact of current treatment with Biphasic
Insulin Aspart 30 (NovoMix 30) found that treatment
satisfaction signiﬁcantly (P\0.001) improved with treat-
ment. Change scores ranged from 11.0 points (Symptoms
domain) to 28.7 points (Efﬁcacy domain). Effect size cal-
culations were moderate to high ranging from 0.55
(Symptoms domain) to 1.69 (Efﬁcacy domain) (Table 4).
A regression analysis examining the impact of experienc-
ing treatment side effects (weight gain, minor hypoglycemic
events) and patient achievement of physician-determined
HbA1c found that weight gain and experiencing minor
hypoglycemic events were negatively associated with
satisfaction in each of the DiabMedSat domains as well as
the total score. Achievement of HbA1c levels was associ-
ated with greater satisfaction in Symptoms and Burden
domains. Correlations between the DiabMedSat domains
Table 1 Demographics data:
DiabMedSat sub-sample
(n = 17,488)
a Not mutually exclusive
categories
Country
N (%) Canada 438 (2.5%)
N (%) China 12,758 (73.0%)
N (%) India 349 (2.0%)
N (%) Italy 33 (0.2%)
N (%) Japan 144 (0.8%)
N (%) Poland 3,186 (18.2%)
N (%) Russia 580 (3.3%)
Age
Mean (SD) (n = 17,486) 57.2 (12.0) Range 8–99
Gender
N (%) Male 9,904 (56.6%)
N (%) Female 7,584 (43.4%)
Body mass index (BMI)
Mean (SD) baseline (n = 17,483) 26.2 (4.8) Range 12.8–66.6
HbA1c
Mean (SD) most recent (n = 12,981) 9.2 (1.9) Range 4–16
Diabetes duration (years)
Mean (SD) (n = 17,481) 6.9 (5.2) Range 0–42
No. of diabetes-related complications
Mean (SD) baseline (n = 14,302) 0.6 (0.5) Range 0–1
Pre-study therapy
N (%) OAD (oral anti-diabetics) only 15,816 (90.4%)
N (%) insulin only 961 (5.5%)
N (%) insulin ? OAD 711 (4.1%)
Reasons for starting NovoMix 30
a
N (%) easy start of therapy 11,388 (65.1%)
N (%) easy identiﬁcation of insulin therapy 8,673 (49.6%)
N (%) to improve HbA1c 13,907 (79.5%)
N (%) to improve FBG 14,094 (80.6%)
N (%) to improve PPBG 13,524 (77.3%)
N (%) reduce risk of hypoglycemia 7,138 (40.8%)
N (%) patient dissatisfaction with previous therapy 9,238 (52.8%)
N (%) side effects from previous therapy 3,798 (21.7%)
N (%) change due to insulin pen 1,253 (7.2%)
N (%) allow for mealtime administration 7,610 (43.5%)
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123and minor hypoglycemic episodes and weight gain were
small (0.007–0.055) minimizing the potential multicollin-
earity in the regression models (Table 5).
A ﬁnal regression analysis examined the combined
signiﬁcant predictors from both the pretreatment and the
current treatment analyses. No differences were found
when all pretreatment and during treatment factors were
examined in combination as when the pretreatment and
during treatment variables were examined separately with
the exceptions that age dropped signiﬁcance in Efﬁcacy
and reaching the physicians HbA1c goal dropped signiﬁ-
cance in the Symptom domain.
Discussion
Treatment satisfaction is an important factor in determining
the success of treatment in diabetes. This study found that
patients who were treated with Biphasic Insulin Aspart 30
(NovoMix 30) reported improved treatment satisfaction
after 26 weeks of treatment and that the improvement in
treatment satisfaction is large enough to be considered
clinically meaningful to patients.
Treatment satisfaction is a complex concept encompass-
ing not only satisfaction with treatment efﬁcacy but also the
burden and side effects of treatment [40]. Additionally, as
Table 2 Impact of prior treatment (baseline, week 26 and change)
12 3
OAD only Insulin only Insulin ? OAD Sig.
a
Baseline
DiabMedSat: efﬁcacy Mean 42.3 (16.8) 48.9 (16.5) 45.1 (19.7) .000
N 15,624 947 707
DiabMedSat: symptoms Mean 64.2 (20.3) 67.6 (18.9) 63.2 (20.3) .000
b
N 15,661 950 700
DiabMedSat: burden Mean 63.6 (14.4) 63.9 (13.4) 59.2 (14.6) .000
c
N 15,507 935 698
DiabMedSat: overall Mean 56.6 (13.1) 60.1 (12.8) 55.7 (14.5) .000
d
N 15,816 961 711
Week 26
DiabMedSat: efﬁcacy Mean 71.3 (15.2) 72.3 (13.7) 73.3 (14.7) .001
e
N 15,666 954 703
DiabMedSat: symptoms Mean 75.2 (15.8) 76.0 (14.1) 76.0 (14.3) .148
N 15,678 955 698
DiabMedSat: burden Mean 75.7 (14.1) 75.9 (14.2) 75.1 (14.1) .554
N 15,549 951 691
DiabMedSat: overall Mean 74.0 (11.9) 74.8 (11.2) 74.8 (11.4) .067
N 15,797 961 710
Change
DiabMedSat: efﬁcacy Mean 29.0 (22.0) 23.4 (19.7) 28.4 (23.8) .000
f
N 15,479 940 699
DiabMedSat: symptoms Mean 11.1 (21.0) 8.3 (19.4) 13.1 (21.3) .000
N 15,525 944 688
DiabMedSat: burden Mean 12.2 (18.0) 12.0 (17.5) 16.0 (18.9) .000
g
N 15,249 925 679
DiabMedSat: overall Mean 17.4 (16.0) 14.6 (14.7) 19.1 (17.3) .000
N 15,797 961 710
a Analysis of variance (ANOVA)
b Using ANOVA contrasts: column 1 and 3 are not signiﬁcant (P = 0.199)
c Using ANOVA contrasts: column 1 and 2 are not signiﬁcant (P = 0.452)
d Using ANOVA contrasts: column 1 and 3 are not signiﬁcant (P = 0.092)
e Using ANOVA contrasts: column 2 and 3 are not signiﬁcant (P = 0.120)
f Using ANOVA contrasts: column 1 and 3 are not signiﬁcant (P = 0.479)
g Using ANOVA contrasts: column 1 and 2 are not signiﬁcant (P = 0.710)
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123previously suggested, factors that inﬂuence treatment satis-
faction may vary depending upon the stage of treatment so
that certain factors should be considered when starting a
patient on a new treatment compared to once a patient has
been on a treatment [16]. For example, age was shown to
have a signiﬁcant inﬂuence on satisfaction with treatment
efﬁcacy at study start, however, not after 26 weeks of
treatment. Similarly, reaching HbA1c goal was signiﬁcant
after 26 weeks of treatment, but only when prior treatment
variables were not taken into account. This suggests that
assessingtreatmentsatisfactionshouldbeanongoingpartof
a treatment plan in order to fully and currently understand
how patients perceive their treatments.
When interpreting the inﬂuence of prior treatment fac-
tors, it is possible that response shift, the change in a
person’s perception or valuation of a concept over time
[43] may explain, in part or in full, the ﬁnding that duration
of disease was signiﬁcantly related to increased overall
satisfaction as well as with treatment efﬁcacy and burden
satisfaction. Patients having diabetes longer may accom-
modate and adapt to their disease and treatment over time
thus ﬁnding diabetes less difﬁcult to manage.
This study found that switching from a pretreatment oral
medication to injectable insulin did not lower treatment
satisfaction or increase treatment burden due to injectable
insulin. In fact, patients previously on an oral treatment
Table 3 Impact of pre-study variables on satisfaction
Pre-study variables DiabMedSat (week 26) (coefﬁcient, t-ratio)
Overall*** Efﬁcacy** Symptoms*** Burden***
Intercept 72.520 (132.5)*** 70.973 (101.7)*** 74.004 (105.4)*** 72.828 (111.1)***
Age (years) 0.034 (3.8)*** 0.032 (2.8)** 0.020 (1.7) 0.047 (4.3)***
Gender (Female = 1) 0.254 (1.2) .291 (1.1) 0.249 (1.0) 0.267 (1.1)
Diabetes duration (years) 0.016 (0.7) -0.033 (-1.2) 0.009 (0.3) 0.070 (2.7)**
Prior treatment (1 = OAD only)
(0 = insulin only)
-1.171 (-3.8)*** -1.124 (-2.8)** -2.382 (-6.0)*** 0.043 (0.1)
Diabetic-related comorbidities
(before study) (1 = Yes)
0.188 (0.9) 0.092 (0.3) 1.204 (4.3)*** -0.670 (-2.6)*
F-stat
a 8.410*** 3.678** 14.153*** 8.275***
* P\0.05; ** P\0.01, *** P\0.001
a The F-statistic is a hypothesis test that all variables as a group in the model signiﬁcantly affect the dependent variable
Table 4 Impact of current treatment (NovoMix 30) on satisfaction
Total sample n Baseline mean (SD) Week 26 mean (SD) Change score mean (SD) t-Stat (sig.) Effect size
a
DiabMedSat
Efﬁcacy 17,118 42.8 (16.9) 71.5 (15.1) 28.7 (21.9) 171.0 (.000) 1.698
Symptoms 17,157 64.3 (20.2) 75.3 (15.6) 11.0 (20.9) 68.9 (.000) 0.545
Burden 16,853 63.4 (14.3) 75.7 (14.1) 12.4 (18.0) 88.9 (.000) 0.867
Total 17,468 56.7 (13.2) 74.1 (11.9) 17.4 (16.0) 143.6 (.000) 1.318
a Effect size, mean change in score divided by the standard deviation of mean baseline score
Table 5 Impact of current study treatment variables on satisfaction
During study treatment variables DiabMedSat (week 26) (coefﬁcient, t-ratio)
Overall*** Efﬁcacy*** Symptoms*** Burden***
Intercept 76.720 (53.9)*** 69.174 (37.9)*** 80.670 (43.0)*** 79.608 (46.4)***
Weight gain (ﬁnal minus baseline, positive values = gain) -0.218 (-8.9)*** -0.202 (-6.4)*** -0.341 (-10.5)*** -0.107 (-3.6)***
All minor hypoglycemic events during 4 weeks, ﬁnal visit -0.482 (-5.2)*** -0.415 (-3.5)*** -0.603 (-5.0)*** -0.402 (-3.6)***
Achieved physicians level of HbA1c (0 = No) -2.453 (-1.7) 2.435 (1.3) -5.203 (-2.8)** -3.812 (-2.2)*
F-stat 37.585*** 18.963*** 48.909*** 10.729***
* P\0.05; ** P\0.01, *** P\0.001
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123alone had almost identical scores in satisfaction with
amount of treatment burden at week 26 as those who had
previously been on insulin (75.7 vs. 75.9) as well as a
greater increase in overall treatment satisfaction than those
previously on an insulin treatment alone (17.4 vs. 14.6).
Additionally, the greatest improvement between oral and
insulin was for the Efﬁcacy domain (29.0 vs. 23.4). Efﬁ-
cacy has been shown to be a major driver in determining
treatment satisfaction [2]. In the DiabMedSat, efﬁcacy
items include concepts of keeping blood sugar stable as
well as impact on physical and emotional well-being sug-
gesting that for patients, efﬁcacy may be deﬁned more
broadly than just HbA1c levels.
When examining ongoing treatment factors that inﬂu-
ence treatment satisfaction, it is clear that the occurrence of
side effects is a major issue for patients and impacts
treatment satisfaction overall as well as for each domain. In
fact, the occurrence of side effects was more important
than reaching HbA1c goal in determining treatment satis-
faction. The inﬂuences of weight gain and major hypo-
glycemic events on treatment satisfaction have been
previously shown [44]. The major inﬂuence of even minor
hypoglycemic events is surprising and is suggestive that
more research is needed to fully understand how and at
what cost these minor hypoglycemic events have on
treatment satisfaction and clinical outcomes.
It should be noted that there were 12 children (under age
18) included in the analyses and that the inﬂuence of the
variables of interest on treatment satisfaction on children
may differ from adults. Unfortunately, this sub-sample was
too small to allow for any meaningful comparisons
between children and adults. Also, unexamined in this
study are potential differences in ﬁndings among countries,
which should be examined in future research. Finally, we
admit to certain limitations of observational studies which
are in contrast to a controlled clinical trial design that
examines treatment impact under highly structured and
prescribed conditions. Although our data analysis set
included about a third of the total global cohort (17,488/
52,419, 33.3%), the demographic characteristics and out-
comes were very much similar to those of the global cohort
reported previously [31]. Other limitations of such studies
have been discussed at some length previously and include
factors such as the heterogeneity of healthcare systems
across the participating countries, a lack of control groups
for outcome comparison and the potential for patient recall
bias during data collection [45]. The above factors also
complicate the selection of predictor variables for regres-
sion analyses. However, given the large sample size, we do
consider the analyses quite suggestive and clinically rele-
vant. Observational data does not replace clinical trial data,
but rather offers additional effectiveness information in a
real-world setting to support clinical trial effectiveness
ﬁndings. Therefore, these ﬁndings may be more general-
izable and relevant for a wide spectrum of clinician and
treatment settings and provide greater insights into treat-
ment satisfaction for the ‘‘average’’ person with diabetes.
Additionally, the signiﬁcant factors identiﬁed here which
impact treatment satisfaction are most certainly not the
only factors which have an effect, and further research is
needed to identify these additional factors.
Conclusions
Patient treatment satisfaction can be a key factor inﬂu-
encing compliance and disease management in diabetes.
This study found that patients who were treated with
Biphasic Insulin Aspart 30 (NovoMix 30) reported
improved treatment satisfaction after 26 weeks of treat-
ment and that the improvement in treatment satisfaction
was large enough to be considered clinically meaningful to
patients. Factors that inﬂuence treatment satisfaction may
vary depending upon the stage of treatment.
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